CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 116 enrolled
Drug / intervention
bevacizumab +7 moredrug
Likely dose
bevacizumab 15 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00550537
NCT00550537Phase 2Completed
CompareCT.gov

A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients With Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Treated With the EGFR-TKI, Erlotinib

Vanderbilt-Ingram Cancer Center·interventional·Posted Oct 30, 2007·Updated Jun 8, 2017

In Brief

A Phase 2 clinical trial evaluating bevacizumab, carboplatin, and 6 other interventions for Lung Cancer. Completed, enrolled 116 participants across 7 sites.

Detailed Summary

RATIONALE: Studying samples of tumor tissue, blood, and urine in the laboratory from patients receiving erlotinib may help doctors predict how patients will respond to treatment. PURPOSE: The phase II trial is studying proteomic profiling to see how well it predicts response in patients receiving erlotinib for stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2007
Enrollment StartOct 1, 2007
Primary CompletionSep 1, 2011
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.7 years ago

Interventions

bevacizumabdrug

15 mg/m2 given through a vein for every 3 weeks

carboplatindrug

AUC = 6 given through a vein on day 1 of each cycle.

erlotinib hydrochloridedrug

150 mg taken by mouth daily

paclitaxeldrug

200 mg/m2 given through a vein on day 1 of each cycle.

gene expression analysisgenetic

Blood and tissue collection.

protein expression analysisgenetic

Blood and tissue collection.

proteomic profilinggenetic

Blood and tissue collection.

laboratory biomarker analysisother

Blood and tissue collection.